The studies all answer key clinical questions, highlighting a variety of new technologies, drugs and techniques.

Wearable activity trackers found that PE patients were more active if they underwent mechanical thrombectomy than if they were just put on anticoagulation therapy alone.

TAVR Assist+ was built to capture patient measurements and perform other straightforward tasks. This gives cardiologists more ...

The implantable device, which first gained U.S. Food and Drug Administration (FDA) approval in April, was designed to provide high-quality patient care and simplify electrophysiology workflows. It ...

MRI scans have traditionally been used for extracellular volume assessments. That is starting to change, however, as cardiac ...

Ohio-based Riverain Technologies is now making its FDA-cleared suite of AI tools available through RapidAI’s Rapid Enterprise ...

For hospitals, health systems and physician groups, effective cardiovascular strategic planning is the foundation for better ...

The AHA recognized more than 2,700 U.S. healthcare organizations for managing patients with high blood pressure, high ...

The U.S. Centers for Medicare and Medicaid Services (CMS) is considering another substantial update to its transcatheter ...

Orforglipron was linked to consistent weight loss in addition to reductions in waist circumference, systolic blood pressure, ...

Heart failure patients with a CardioMEMS implant can now monitor their own pulmonary artery pressure reading and receive ...

The U.S. Food and Drug Administration (FDA) has accepted CeleCor Therapeutics ' new drug application (NDA) for zalunfiban (Disaggpro). The investigational drug was developed to treat ST-elevation ...